{"Clinical Trial ID": "NCT01923168", "Intervention": ["INTERVENTION 1:", "- Alpelisib + Letrozole", "Participants took 300 mg of alpelisib once daily plus 2.5 mg of letrozole once daily.", "INTERVENTION 2:", "Placebo + Letrozole", "Participants took corresponding Placebo (300 mg of alpelisib once daily/buparlisib 100 mg once daily or 5 days on 2 days off) plus Letrozole 2.5 mg once daily."], "Eligibility": ["Incorporation criteria:", "The patient is an adult, an 18-year-old woman at the time of informed consent.", "The patient has a histologically and/or cytologically confirmed diagnosis of breast cancer", "The patient is postmenopausal.", "The patient has T1c-T3, any N, M0, operational breast cancer", "Patients should have a measurable disease", "The patient has a diagnostic biopsy for the analysis of the PIK3CA mutation and the Ki67 level.", "The patient has positive breast cancer with estrogen and/or progesterone according to local laboratory tests", "The patient has a negative HER2 breast cancer defined as a negative in situ hybridization test or an IHC status of 0 or 1+ according to local laboratory tests", "- Exclusion criteria:", "The patient has a local recidivant or metastatic disease", "The patient received systemic treatment (e.g. chemotherapy, targeted treatment, immunotherapy) or radiation therapy for a current breast cancer disease prior to randomization.", "* Patients with poorly controlled type 1 diabetes or type 2 diabetes", "\u2022 History of acute pancreatitis within one year of entry into the study", "Uncontrolled hypertension"], "Results": ["Performance measures:", "\u2022 Complete pathological response (RCP) by investigator for Alpelisib vs Placebo for PIK3CA Mutant Cohort", "The complete pathological response (CPR) defined as the absence of any residual invasive cancer on the hematoxyline and eosin of the resected breast sample and all ipsilateral lymph nodes sampled after 24 weeks of local evaluation (ypT0/Tis ypN0). Patients who experienced disease progression during neoadjuvant therapy, or who did not receive surgery for any reason, or who received anti-neoplastic treatment other than the drug(s) studied prior to surgery were considered non-responders for the calculation of SPC.", "Time limit: after 24 weeks of treatment", "Results 1:", "Title of the arm/group: Alpelisib + Letrozole", "Description of the arm/group: Participants took 300 mg of alpelisib once daily plus 2.5 mg of letrozole once daily.", "Total number of participants analysed: 60", "Type of measurement: Number", "Unit of measure: Percentage of participants 1.7 (0.2 to 6.3)", "Results 2:", "Title of the arm/group: Placebo + Letrozole", "Description of the arm/group: Participants took the corresponding placebo (300 mg alpelisib once daily/buparlisib 100 mg once daily or 5 days on 2 days off) plus letrozole 2.5 mg once daily.", "Total number of participants analysed: 67", "Type of measurement: Number", "Unit of measure: Percentage of participants 3.0 (0.8 to 7.7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 21/130 (16.15 per cent)", "Atrial fibrillation 0/130 (0.00 %)", "Cardiac disorder 0/130 (0.00 %)", "Heart failure 1/130 (0.77%)", "- stress cardiomyopathy 1/130 (0.77%)", "Iritis 0/130 (0.00 %)", "- Collision 1/130 (0.77%)", "Diarrhoea 1/130 (0.77%)", "Nausea 1/130 (0.77%)", "Stomatitis 1/130 (0.77%)", "- Vomiting 1/130 (0.77%)", "Disease progression 1/130 (0.77%)", "Adverse Events 2:", "Total: 22/81 (27.16 per cent)", "Atrial fibrillation 2/81 (2.47%)", "1/81 (1.23%)", "Heart failure 0/81 (0.00 %)", "- stress cardiomyopathy 0/81 (0.00 %)", "Iritis 1/81 (1.23%)", "Colite 2/81 (2.47 %)", "Diarrhoea 1/81 (1.23%)", "Nausea 0/81 (0.00 %)", "- Stomatitis 0/81 (0.00 %)", "Vomiting 0/81 (0.00 %)", "Rate of disease progression 0/81 (0.00 %)", "General deterioration of physical health 1/81 (1.23 per cent)"]}